C4 Therapeutics (CCCC) Shares Outstanding (2019 - 2026)

C4 Therapeutics has reported Shares Outstanding for 8 years, with the latest figure at $104.0 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 46.55% year-over-year to $104.0 million; the trailing twelve-month figure through Mar 2026 stood at $104.0 million (up 46.55% YoY), and the FY2025 full-year result was $96.9 million, up 37.22% from the prior year.
• Shares Outstanding for Q1 2026 stood at $104.0 million, up from $96.9 million in the prior quarter.
• The five-year high for Shares Outstanding was $104.0 million in Q1 2026, with the low at $48.8 million in Q1 2022.
• Average Shares Outstanding over 5 years is $64.7 million, with a median of $68.8 million recorded in 2024.
• Year-over-year, Shares Outstanding gained 0.38% in 2023 and soared 46.55% in 2026.
• Tracing CCCC's Shares Outstanding over 5 years: stood at $49.0 million in 2022, then climbed by 23.49% to $60.5 million in 2023, then climbed by 16.8% to $70.6 million in 2024, then jumped by 37.22% to $96.9 million in 2025, then grew by 7.35% to $104.0 million in 2026.
• The last three Shares Outstanding figures came in at $104.0 million (Q1 2026), $96.9 million (Q4 2025), and $74.2 million (Q3 2025), per Business Quant data.

Peer Comparison